CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 175,587	$ 90,326
Accounts receivable, net	337,593	269,312
Inventories	217,597	195,019
Other current assets	137,902	124,982
Total current assets	868,679	679,639
Long-Term Assets:
Property and equipment, net	547,624	533,845
Operating lease right-of-use assets	84,735	80,607
Goodwill	238,100	239,724
Intangible assets, net	53,467	58,468
Other long-term assets	254,802	240,192
Total long-term assets	1,178,728	1,152,836
TOTAL ASSETS	2,047,407	1,832,475
Current Liabilities:
Accounts payable	71,933	72,172
Accrued liabilities	362,326	322,938
Line of credit	0	288,765
Current portion of long-term debt	49,983	0
Current portion of deferred revenue	42,599	41,462
Total current liabilities	526,841	725,337
Long-Term Liabilities:
Deferred income tax liabilities	27,590	33,024
Long-term debt, net of current portion	853,316	698,910
Long-term deferred revenue, net of current portion	48,226	48,743
Long-term operating lease liabilities	70,655	67,472
Other long-term liabilities	79,664	81,164
Total long-term liabilities	1,079,451	929,313
Total liabilities	1,606,292	1,654,650
Commitments and Contingencies (Note 16)
Stockholders’ Equity:
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued:106,282 shares in 2020 and 105,711 shares in 2019; Outstanding: 85,300 shares in 2020 and 85,471 shares in 2019	10,628	10,571
Additional paid-in capital	1,274,069	1,213,517
Deferred stock units: Outstanding: 147 units in 2020 and 143 units in 2019	5,411	4,462
Retained earnings	2,000,805	1,595,648
Accumulated other comprehensive loss	(61,925)	(46,182)
Treasury stock, at cost: 20,982 shares in 2020 and 20,240 shares in 2019	(2,788,412)	(2,600,543)
Total IDEXX Laboratories, Inc. stockholders’ equity	440,576	177,473
Noncontrolling interest	539	352
Total stockholders’ equity	441,115	177,825
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 2,047,407	$ 1,832,475